185 related articles for article (PubMed ID: 14532782)
1. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Di Silverio F; Sciarra A
J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
[TBL] [Abstract][Full Text] [Related]
2. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
3. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
4. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
[TBL] [Abstract][Full Text] [Related]
5. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Cerulli C; Sciarra A; Salvatori G; Di Silverio F
Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212
[TBL] [Abstract][Full Text] [Related]
6. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
8. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
[TBL] [Abstract][Full Text] [Related]
9. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
10. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
11. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
12. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer.
Kalkner KM; Acosta S; Thorsson O; Frederiksen H; Nilsson A; Gustavsson B; Elingsbo M; Stridsberg M; Abrahamsson PA
Prostate Cancer Prostatic Dis; 2006; 9(1):92-8. PubMed ID: 16231013
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
[TBL] [Abstract][Full Text] [Related]
14. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.
Maulard C; Richaud P; Droz JP; Jessueld D; Dufour-Esquerré F; Housset M
Cancer Chemother Pharmacol; 1995; 36(3):259-62. PubMed ID: 7540120
[TBL] [Abstract][Full Text] [Related]
18. Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience.
Sciarra A; Gentile V; Cattarino S; Gentilucci A; Alfarone A; D'Eramo G; Salciccia S
Int J Urol; 2015 Jan; 22(1):98-103. PubMed ID: 25186970
[TBL] [Abstract][Full Text] [Related]
19. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]